Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP.

Blood. 2007 Jan 1;109(1):52-7. Epub 2006 Aug 1.

2.

Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.

Xie M, Jiang Q, Xie Y.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12. Review.

PMID:
25042977
3.

Decitabine in the treatment of myelodysplastic syndromes.

Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F.

Expert Rev Anticancer Ther. 2010 Jan;10(1):9-22. doi: 10.1586/era.09.164. Review.

PMID:
20014881
4.

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R.

Oncologist. 2005 Mar;10(3):176-82. Review.

5.

[Hypomethylating agents for the treatment of myelodysplastic syndromes].

Itzykson R, Fenaux P.

Bull Cancer. 2011 Aug;98(8):927-34. doi: 10.1684/bdc.2011.1411. Review. French.

6.

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.

Silverman LR, Mufti GJ.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S12-23. Review.

PMID:
16341236
7.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
8.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301
9.
10.

Safety and efficacy of azacitidine in myelodysplastic syndromes.

Vigil CE, Martin-Santos T, Garcia-Manero G.

Drug Des Devel Ther. 2010 Sep 24;4:221-9. Review.

11.

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.

Hackanson B, Robbel C, Wijermans P, Lübbert M.

Ann Hematol. 2005 Dec;84 Suppl 1:32-8. Review.

PMID:
16292549
12.

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

Joeckel TE, Lübbert M.

Semin Hematol. 2012 Oct;49(4):330-41. doi: 10.1053/j.seminhematol.2012.08.001. Review.

PMID:
23079063
13.

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.

Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, Patnaik MM.

Clin Epigenetics. 2016 Jun 14;8:68. doi: 10.1186/s13148-016-0233-2. eCollection 2016. Review.

14.

The role of decitabine in the treatment of myelodysplastic syndromes.

Atallah E, Kantarjian H, Garcia-Manero G.

Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review.

PMID:
17163808
15.

Pharmacokinetic evaluation of decitabine for the treatment of leukemia.

Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):661-72. doi: 10.1517/17425255.2011.575062. Review.

PMID:
21500965
16.

5-azacytidine and decitabine monotherapies of myelodysplastic disorders.

Kuykendall JR.

Ann Pharmacother. 2005 Oct;39(10):1700-9. Epub 2005 Sep 6. Review.

PMID:
16144884
17.

Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

Steensma DP, Stone RM.

Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. doi: 10.1016/j.hoc.2010.02.012. Review.

PMID:
20359633
18.

Decitabine for acute myeloid leukemia.

Marks PW.

Expert Rev Anticancer Ther. 2012 Mar;12(3):299-305. doi: 10.1586/era.11.207. Review.

PMID:
22369322
19.

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.

Adès L, Itzykson R, Fenaux P.

Semin Hematol. 2012 Oct;49(4):323-9. doi: 10.1053/j.seminhematol.2012.09.002. Review.

PMID:
23079062
20.

Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.

Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H.

Cancer. 2008 Jun;112(11):2341-51. doi: 10.1002/cncr.23463. Review.

Supplemental Content

Support Center